

533 RECUPCT/PTO 13 SEP 2001

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.:

DC-0155

Inventors:

Brinckerhoff and Rutter

Serial No.:

09/856,749

Filing Date:

Not yet assigned

Examiner:

Not yet assigned

Group Art Unit:

Not yet assigned

Title:

Methods of Diagnosing, Prognosticating and Treating Matrix Metalloproteinase-1

Related Diseases via a Matrix

Metalloproteinase-1 Single Nucleotide

Polymorphism

I, Kathleen A. Tyrrell, Registration No. 38,350, certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

On this date: September 10, 2001

Kathleen A. Tyrrell/ Registration No. 38,350

BOX SEQUENCE

Assistant Commissioner for Patents Washington, DC 20231

Sir:

RESPONSE TO NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURE

In response to the "Notification to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" dated August 1, 2001, a response to which is due October 1, 2001, enclosed herewith is:

() Amendment under 1.825;

- (XX) Statement to Support Filing and Submission in Accordance with 37 CFR §§1.821 through 1.825;
- () Substitute pages of the Sequence Listing;
- (XX) Substitute copy of the computer readable form of Sequence Listing;
- (XX) Copy of Notification to Comply with Requirements for Patent Applications containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
- () Petition for Three (3) Month Extension of Time;
- () Other: ____.

The Commissioner is hereby authorized to charge any underpayment associated with this communication or credit any overpayment to Deposit Account No. 50-1619. This sheet is attached in duplicate.

Respectfully submitted,

Kathleen A. Tyrrell

Registration No. 38,350

Date: September 10, 2001

Licata & Tyrrell P.C. 66 E. Main Street Marlton, New Jersey 08053

(856) 810-1515

United States Patent and Tradi	EMARK OFFICE	-		
OIPM		Con United State	umissioner for Patents, B es Patent and Trademark Washington, D.C. www.u	Office
U.S. APPLICATION NO	FIRST NAMED APPLICANT	A	TTY. DOCKET NO.	
0985674 SEP 1 3 2001 🕏	BRINCKERHOFF	С	DC-0155	1
3		INTERNATIONAL APPLICATION NO.		ı
	System	PCT/US99/26610		
	Report	I.A. FILING DATE	PRIORITY DATE	4
Docket Book	Book	10 NOV 99	30 NOV 98	Mitice &
!		DATE MAILED:	1 AUG 2001	
NOTIFICATION TO COMPLY W CONTAINING NUCLEOTIDE	TH REQUIREMENTS SEQUENCE AND/OR DISCLOSURES	FOR PATENT APP AMINO ACID SEQ	30 NOV 98 AUG 2005 PLICATIONS UENCE	2-1-62
Applicant has submitted papers under 35	U.S.C. 371 to enter the	national stage in the	United States of	

Applicant has submitted papers under 35 U.S.C. 371 to enter the national stage in the United States of America. The items indicated below, however, are missing. The period within which to correct the deficiency noted below and avoid abandonment is set forth in the accompanying Notification.

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

The application fails to comply with the red	quirements of 37 CFR 1.821-1.825.
This application does not contain, a "Seque	ence Listing" as a separate part of the
disclosure on paper copy or compact disc,	
A copy of the "Sequence Listing" in compu	iter readable format has not been submitted as
required by 37 CFR 1.821(e).	
	iter readable form has been submitted. The
content of the computer readable form, how 37 CFR 1.822 and/or 1.832, as indicated or Sequence Listing."	vever, does not comply with the requirements of the attached marked-up copy of the "Raw
	filed with this application has been found to be
damaged and/or unreadable as indicated on substitute computer readable form must be	the attached CRF Diskette Problem Report. A submitted as required by 37 CFR 1.825(d).
The paper copy or compact disc of the "Sec	
computer readable form of the "Sequence Other:	Listing as required by 37 CFR 1.821(e).
·	
*	
APPLICANT MUST PROVIDE:	
An initial or substitute computer readable for	orm (CRF) of the "Sequence Listing"
turned A	act disc of the "Sequence Listing," as well as an
An initial or substitute paper copy or compared amendment directing its entry into the spec	
A statement that the contents of the paper of	r compact disc and the computer readable form
are the same and, where applicable, include	
1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.	
1.021(0), 1.021(1), 1.021(5), 1.005(0) 01 1.	023(C).
FOR QUESTIONS REGARDING COMPLIANCE W. CALL:	ITH THESE REQUIREMENTS, PLEASE
(703) 308-4216, for Rules interpretation,	
(703) 308-4212, for CRF submission help,	
(703) 287-0200, for PatentIn software help.	$\Lambda \sim$
	Charitta A Burt Paralegal
	Telephone: 703-305-3734
FORM PCT/DO/EO/920 (March 2001)	\vee

The Committee of the Co